Navigation Links
Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
Date:9/18/2007

umor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart failure, and/or new onset of decreased left ventricular ejection fraction has been reported, including reports in patients with few or no risk factors for decreased left ventricular ejection fraction. There have been rare reports of acute diffuse infiltrative pulmonary disease of unknown etiology such as pneumonitis, interstitial pneumonia, lung infiltration and Acute Respiratory Distress Syndrome in patients receiving VELCADE. Some of these events have been fatal. A higher proportion of these events have been reported in Japan. There have been rare reports of RPLS in patients receiving VELCADE. RPLS is a rare, reversible, neurological disorder which can present with seizure, hypertension, headache, lethargy, confusion, blindness, and other visual and neurological disturbances. VELCADE is associated with thrombocytopenia and neutropenia. There have been reports of gastrointestinal and intracerebral hemorrhage in association with VELCADE. Transfusions may be considered. Complete blood counts (CBC) should be frequently monitored during treatment with VELCADE. Rare cases of acute liver failure have been reported in patients receiving multiple concomitant medications and with serious underlying medical conditions.

Safety Data of VELCADE as a single-agent: In 1163 patients in multiple myeloma and mantle cell lymphoma studies, the most commonly reported adverse events were asthenic conditions (64%), nausea (55%), diarrhea (52%), constipation (41%), peripheral neuropathy (39%), thrombocytopenia (36%), appetite decrease, including reports of anorexia (36%), pyrexia (34%), vomiting (33%) and anemia (29%). Twenty percent of patients re
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 In response to urgent requests from the Deputy ... Sierra Leone , Direct Relief delivered two 10-bed medical ... treatment of local health workers who contract Ebola while fighting ... care center was constructed for foreign health care workers who ... for local Sierra Leonean health workers. With ...
(Date:12/22/2014)... N.J. , Dec. 22, 2014  CytoSorbents ... marketing its CytoSorb® blood purification technology to help ... patients in 28 countries worldwide, today announced the ... , MD, FACS, as its Senior Vice President ... Dr. Di Russo is ...
(Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... of the "US Self-monitoring Blood Glucose Market" ... http://photos.prnewswire.com/prnh/20130307/600769 This market insight focuses on ... the United States . Reimbursement analysis ... Thorough product analyses for more than 73 SMBG meters ...
Breaking Medicine Technology:First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5US Self-monitoring Blood Glucose Market 2
... VIEW, Calif., Nov. 3 VIVUS, Inc. ... Peter Tam to president of VIVUS. In this position, ... VIVUS, development and business functions, including corporate and product ... and chemistry, manufacturing and controls. Leland Wilson, formerly president ...
... The owner and operator of a Houston-area durable ... the Medicare program, announced Assistant Attorney General of the ... of the Southern District of Texas and Daniel R. ... Human Services (HHS). , Noel Wayne Jhagroo, 47, pleaded ...
Cached Medicine Technology:VIVUS Announces Promotion of Peter Tam to President 2VIVUS Announces Promotion of Peter Tam to President 3Medical Equipment Company Owner Pleads Guilty to Fraud Scheme Involving Nutritional Supplies and "Arthritis Kits" 2Medical Equipment Company Owner Pleads Guilty to Fraud Scheme Involving Nutritional Supplies and "Arthritis Kits" 3
(Date:12/26/2014)... Plugin and template developers from Pixel ... for Final Cut Pro X. , “TransPack Volume 5 gives ... pull off an industry professional look” Said Christina Austin, CEO ... TransPack Volume 5, a new level of professionalism will become ... over 50 Final Cut Pro X transitions featuring organic animations. ...
(Date:12/26/2014)... India Network Foundation, a non-profit US based ... today a new version of “ EasySelect ”, a ... plan for their visiting parents. The technology tool is ... process when choosing an insurance plan by showing the ... few clicks. Many elderly Asian Indian parents often find ...
(Date:12/26/2014)... DW-InductionHeating.com (DaWei Induction Heating Co.) is a comprehensive high-tech ... marketing of a series of induction heating equipment. Today, ... of induction brazing equipments . , According to ... refers to the joining of two or more ... manager says that there are fundamental differences in the ...
(Date:12/25/2014)... The microscopy market is estimated to ... $5,756.0 million by 2019. Optical microscopy is the ... microscopes product segment is expected to show the ... focus on nanotechnology, technological advancements, and increasing federal ... , Get Full Copy of Report @ ...
(Date:12/25/2014)... The click strand woven bamboo ... durability. Today, the business announces a click strand ... Jan. 30, 2015. , Click strand woven bamboo ... is a well-known brand in the bamboo industry. ... a reliable bamboo flooring supplier. , “We are ...
Breaking Medicine News(10 mins):Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2
... in Colorado,s metro, markets the Complete Picture ... Aug. 4 Anthem Blue Cross and Blue ... industry-leading transparency,initiative. Now, members in Colorado,s metro markets ... that provides total estimated costs,associated with all aspects ...
... Mo. Injuries are the leading cause of death ... to the Centers for Disease Control and Prevention. In ... that children living in households with unrelated adults are ... injuries, compared to children living with two biological parents. ...
... AYSO kids to Lead Soccer Community in Nationwide ... Fundraising Effort to Fight Malaria, NEW YORK, ... and the American Youth Soccer Organization,(AYSO) today announced the "More Than ... partnership is to raise funds and,awareness to help fight malaria and ...
... Minn., Aug. 4 Mayo Clinic,s,medical experts offer breadth ... Olympic Games and Olympians. These are just some of ... meet your needs., Michael Joyner, M.D., is an ... track and field. He says that athletes,performances continue to ...
... ... Expansion Efforts, SAN FRANCISCO, Aug. 4 Quantros, ... healthcare,industry, today announced a series of activities for support of alternative,Web ... are being implemented to ensure those using a browser,other than market ...
... and medication review ... program, ... Stores has officially introduced the Prescription,Rewards Club, a discount drug and personal ... their suppliers, Sav-Mor has responded to competitors, $4,generic drug programs by going ...
Cached Medicine News:Health News:Anthem Blue Cross and Blue Shield in Colorado Introduces Industry Leading and Comprehensive Transparency Initiative to Colorado 2Health News:Anthem Blue Cross and Blue Shield in Colorado Introduces Industry Leading and Comprehensive Transparency Initiative to Colorado 3Health News:Risk of unintentional injury death is high for young children living with unrelated adults 2Health News:FC Barcelona & FCB Foundation, Malaria No More and AYSO Launch Initiative to 'Kick it to Malaria' 2Health News:FC Barcelona & FCB Foundation, Malaria No More and AYSO Launch Initiative to 'Kick it to Malaria' 3Health News:Mayo Clinic Experts Offer Insights on Olympians 2Health News:Mayo Clinic Experts Offer Insights on Olympians 3Health News:Quantros Expanding Support for Alternative Web Browsers 2Health News:Quantros Expanding Support for Alternative Web Browsers 3Health News:Michigan-based Company Introduces Discount Prescription Drug Program 2
For the quantitative in vitro determination of Magnesium in serum, plasma and urine...
The LDH method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of lactate dehydrogenase activity in serum or plasma...
For the quantitative in vitro determination of Lactate Dehydrogenase (LD) in serum and plasma....
For the quantitative in vitro determination of Anti-Streptolysin-O (ASO) in serum....
Medicine Products: